Director/PDMR Shareholding

RNS Number : 0887U

Somero Enterprises Inc.

24 March 2023

 

Somero Enterprises Inc.

("Somero" or the "Company")

Director/PDMR Shareholding

Somero announced that on 23 March 2023 it was notified that Anne Ellis, Director of the Company, purchased 8,000 ordinary shares in the Company at an average price of 364 pence per share.  As a result of the above transaction, Mrs. Ellis has 8,000 Somero ordinary shares.

1.	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Anne Ellis
2.	Reason for the Notification
a)	Position/status	Director
b)	Initial notification/Amendment	Initial notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Somero Enterprises Inc.
b)	LEI	549300OQ2P18NRWBIW58
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the Financial instrument, type of instrument	ordinary shares of $0.001 each ("Ordinary Shares")
	Identification code	USU834501038
b)	Nature of the transaction	Purchase of ordinary shares
c)	Price(s) and volume(s)	Price: 364p Volume: 8,000
d)	Aggregated information: · Aggregated volume · Price	n/a
e)	Date of the transaction	23 March 2023
f)	Place of the transaction	London Stock Exchange, AIM Market (XLON)

The information communicated in this announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No. 596/2014.

For further information, please contact:

Somero Enterprises, Inc.   www.somero.com

Jack Cooney, CEO  [phone]

John Yuncza, President

Enzo LiCausi, CFO

Howard Hohmann, EVP Sales

finnCap Ltd (NOMAD and Broker)

Matt Goode (Corporate Finance)  [phone]

Seamus Fricker (Corporate Finance)

Tim Redfern (ECM)

Alma PR (Financial PR Advisor)     [e-mail]

David Ison    [phone]

Pippa Crabtree

 

END

 

 

DSHFIFVIVEISFIV